Reuters -- The U.S. Food and Drug Administration is allowing Roche Holding AG to resume enrolment to a late-stage trial of Avastin in early-stage HER2-negative breast cancer, the Swiss drugmaker said on Monday.
Reuters -- The U.S. Food and Drug Administration is allowing Roche Holding AG to resume enrolment to a late-stage trial of Avastin in early-stage HER2-negative breast cancer, the Swiss drugmaker said on Monday.
